Redcare Phamacy Unsp/Adr (SAEYY) Q2 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Redcare Pharmacy N.v..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.352 -- 00:00:06.396 Thank you very much and good morning to everybody and a very warm welcome from our side. 00:00:06.396 -- 00:00:11.640 Let's have a look into today's agenda. So first of all, we would like to talk about 00:00:11.640 -- 00:00:17.164 financial performance, then an update on Rx regulatory landscape, 00:00:17.164 -- 00:00:20.706 then an Rx update on our Rx development, 00:00:20.706 -- 00:00:25.910 and then by the end, an outlook and guidance for the remaining part of the year. 00:00:25.910 -- 00:00:30.572 If we go to the next slide, you can start with the financial performance. 00:00:32.600 -- 00:00:37.701 Group sales are up 27% year over year. So we are showing 00:00:37.701 -- 00:00:43.223 a continued strong growth. It's fully organic and it's in both areas, 00:00:43.223 -- 00:00:46.244 non-RX and RX. 00:00:46.244 -- 00:00:50.464 Also in non-RX, we are showing a growth of 18%, 00:00:50.625 -- 00:00:57.047 60% in the DACH region and 26% in the international segment. 00:00:57.047 -- 00:01:01.743 Overall and particularly in Germany with strong market share gains. 00:01:01.743 -- 00:01:07.725 So if we look into the German market and we can see, especially in Q2 of this year, 00:01:07.725 -- 00:01:11.827 that our competition and also brick and mortar is almost flat in sales. 00:01:11.827 -- 00:01:17.049 So we are really lucky to report a continued growth and showing our strength 00:01:17.049 -- 00:01:19.870 in that region and in that market. 00:01:19.870 -- 00:01:24.993 Also fast year over year growth on RX sales in Germany, 155% compared to the first 00:01:24.993 -- 00:01:27.453 half of last year. 00:01:29.636 -- 00:01:35.082 And looking into the EBITDA, we now draw an adjusted EBITDA of 1.9%. 00:01:35.082 -- 00:01:41.987 It's a doubling f...